CA3177243A1 - Methods for treating acute conditions using lipid binding protein-based complexes - Google Patents

Methods for treating acute conditions using lipid binding protein-based complexes

Info

Publication number
CA3177243A1
CA3177243A1 CA3177243A CA3177243A CA3177243A1 CA 3177243 A1 CA3177243 A1 CA 3177243A1 CA 3177243 A CA3177243 A CA 3177243A CA 3177243 A CA3177243 A CA 3177243A CA 3177243 A1 CA3177243 A1 CA 3177243A1
Authority
CA
Canada
Prior art keywords
methods
binding protein
lipid binding
acute conditions
treating acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3177243A
Other languages
English (en)
French (fr)
Inventor
Cyrille TUPIN
Constance PEYROTTES
Ronald Barbaras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abionyx Pharma SA
Original Assignee
Abionyx Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abionyx Pharma SA filed Critical Abionyx Pharma SA
Publication of CA3177243A1 publication Critical patent/CA3177243A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3177243A 2020-04-16 2021-04-15 Methods for treating acute conditions using lipid binding protein-based complexes Pending CA3177243A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063011055P 2020-04-16 2020-04-16
US63/011,055 2020-04-16
US202063092070P 2020-10-15 2020-10-15
US63/092,070 2020-10-15
US202063121640P 2020-12-04 2020-12-04
US63/121,640 2020-12-04
PCT/IB2021/000283 WO2021209823A1 (en) 2020-04-16 2021-04-15 Methods for treating acute conditions using lipid binding protein- based complexes

Publications (1)

Publication Number Publication Date
CA3177243A1 true CA3177243A1 (en) 2021-10-21

Family

ID=76197484

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3177243A Pending CA3177243A1 (en) 2020-04-16 2021-04-15 Methods for treating acute conditions using lipid binding protein-based complexes

Country Status (10)

Country Link
US (1) US20240033322A1 (https=)
EP (1) EP4135747A1 (https=)
JP (1) JP2023522889A (https=)
KR (1) KR20230004605A (https=)
CN (1) CN115427064A (https=)
AU (1) AU2021256086A1 (https=)
CA (1) CA3177243A1 (https=)
IL (1) IL297336A (https=)
MX (1) MX2022012969A (https=)
WO (1) WO2021209823A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297046A (en) 2020-04-16 2022-12-01 Abionyx Pharma Sa Treatment of kidney disease using cer-001
KR20240018430A (ko) * 2021-04-15 2024-02-13 아비오닉스 파마 에스에이 기관 보존 용액에서의 지질 결합 단백질-기반 복합체의 사용
CA3247588A1 (en) * 2022-04-06 2023-10-12 Abionyx Pharma Sa METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID-BINDING PROTEIN COMPLEXES
JP2025519606A (ja) * 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
WO2023237927A2 (en) * 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2024150064A1 (en) * 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy
CN116893215A (zh) * 2023-03-17 2023-10-17 安徽省立医院(中国科学技术大学附属第一医院) 一种用于监测car-t治疗之后crs进程的临床标志物及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128318A (en) 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
JP3754072B2 (ja) 1994-03-22 2006-03-08 リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド 摂食抑制ペプチド
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
AU2001257173B2 (en) 2000-04-21 2005-09-22 Amgen Inc. Apo-ai/aii peptide derivatives
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
EP2343317A1 (en) 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
CA2457840C (en) 2001-08-20 2011-10-11 Zlb Bioplasma Ag Hdl for the treatment of stroke and other ischemic conditions
US7223726B2 (en) 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
AU2003239489A1 (en) 2002-05-17 2003-12-02 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
EP1545576A2 (en) * 2002-07-30 2005-06-29 Esperion Therapeutics Inc. Methods of using non-human animal apoliprotein a-i protein
EP2314285B2 (en) 2003-02-14 2019-09-18 Children's Hospital & Research Center at Oakland Lipophilic drug delivery vehicle and methods of use thereof
CN101076541A (zh) 2004-07-16 2007-11-21 塔夫茨大学信托人 载脂蛋白a1模拟物及其用途
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
AU2006282722A1 (en) 2005-08-26 2007-03-01 Cerenis Therapeutics Holdings S.A. Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
US8541236B2 (en) 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
WO2008104890A2 (en) 2007-02-28 2008-09-04 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
EA201070517A1 (ru) 2007-10-23 2010-12-30 Дзе Кливленд Клиник Фаундейшн Устойчивый к окислителям аполипопротеин а-1 и пептиды-миметики
LT2939683T (lt) 2009-02-16 2017-03-27 Cerenis Therapeutics Holding Sa Apolipoproteino a-i mimetikai
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
EP2673296B1 (en) * 2011-02-07 2018-10-24 Cerenis Therapeutics Holding SA Lipoprotein complexes and manufacturing and uses thereof
JP6438417B2 (ja) 2013-03-15 2018-12-12 セレニス セラピューティクス ホールディング エスアー スフィンゴミエリンおよびジヒドロスフィンゴミエリンの合成のための方法
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
EP2853259A1 (en) * 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
WO2015173633A2 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2018029505A1 (en) * 2016-08-11 2018-02-15 Cerenis Therapeutics Holding Sa Cer-001 therapy for treating familial primary hypoalphalipoproteinemia
FR3100715B1 (fr) * 2019-09-12 2023-09-29 Francais Du Sang Ets Utilisation de HDL dans la prophylaxie de la maladie du greffon contre l’hôte

Also Published As

Publication number Publication date
WO2021209823A1 (en) 2021-10-21
AU2021256086A1 (en) 2022-12-15
KR20230004605A (ko) 2023-01-06
IL297336A (en) 2022-12-01
MX2022012969A (es) 2022-11-09
US20240033322A1 (en) 2024-02-01
JP2023522889A (ja) 2023-06-01
CN115427064A (zh) 2022-12-02
EP4135747A1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
CA3177243A1 (en) Methods for treating acute conditions using lipid binding protein-based complexes
EP4349413A3 (en) Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
EP4389142A3 (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia
JOP20210314A1 (ar) Tigit وجزيئات ربط pd-1/tigit
MX2022009390A (es) Compuestos de unión a il-7r¿¿c.
MXPA06014754A (es) Compuestos y metodos para inhibir la interaccion de las proteinas bcl con los componentes de enlace.
AU2019321490A8 (en) Ox40-binding polypeptides and uses thereof
EP4131800A3 (en) Communication devices and methods for signaling in non-terrestrial networks
WO2021146320A8 (en) Antibody molecules to c5ar1 and uses thereof
EP4335496A3 (en) Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
WO2022261183A3 (en) Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2022115709A3 (en) Methods and composition for treating metabolic syndrome
EP4180985A4 (en) FILE SHARING METHOD, APPARATUS AND SYSTEM
WO2022098890A3 (en) IL-2Rβγc BINDING COMPOUNDS AND USES THEREOF
MX2024013871A (es) Agentes aglutinantes 5t4 y usos de los mismos
EP4685135A3 (en) Compounds and uses thereof for treating inflammation and modulating immune responses
WO2022170008A3 (en) Anti-il1rap antibodies
MX2024015277A (es) Metodos para tratar afecciones agudas utilizando complejos basados en proteinas de union a lipidos
WO2020102243A3 (en) In-flow photooxygenation of aminothienopyridinones generates novel ptp4a3 phosphatase inhibitors
WO2021231803A3 (en) Binding molecules for covid-19 treatment
AU2022300265A1 (en) Methods and compositions for treating gorlin syndrome
EP4329306A4 (en) Methods and devices for processing a code stream, terminal device and storage medium
WO2024058987A3 (en) Polypeptides effective against multiple coronaviruses
MX2024015274A (es) Metodos para tratar afecciones hiperinflamatorias utilizando complejos a base de proteinas de union a lipidos
MX2023005171A (es) Composiciones y metodos para tratamiento de cancer solido.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250411

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250411

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250422

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250822

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250911

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251029

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251029